SciSparc Submits IND Application To The FDA For SCI-110 Phase IIb Clinical Trial For Patients With Tourette Syndrome
Portfolio Pulse from Benzinga Newsdesk
SciSparc Ltd. has submitted an IND application to the FDA for a Phase IIb clinical trial of SCI-110, aimed at treating Tourette Syndrome. The trial will be conducted at multiple international sites, including Yale School of Medicine.
August 23, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SciSparc Ltd. has submitted an IND application to the FDA for a Phase IIb trial of SCI-110 for Tourette Syndrome, potentially advancing its CNS disorder treatment pipeline.
The submission of an IND application to the FDA is a significant regulatory step for SciSparc, indicating progress in their drug development pipeline. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100